Boehringer Ingelheim and Gilead sign license agreement for novel HIV non-catalytic integrase inhibitors

Compounds Represent New Class of Antiretroviral

Ingelheim, Germany and Foster City, California, October 6, 2011 –Boehringer Ingelheim and Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the companies have entered into a licensing agreement, under which Boehringer Ingelheim has granted Gilead exclusive worldwide rights for the research, development and commercialization of its novel non-catalytic site integrase inhibitors (NCINIs) for HIV. This includes the lead compound BI 224436, which has been evaluated in a Phase 1a dose-escalation study to assess bioavailability and pharmacokinetics in healthy volunteers.